839 | AN ONGOING PHASE Ib TRIAL ASSESSING MOSUNETUZUMAB MONOTHERAPY AND COMBINED MOSUNETUZUMAB AND VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Hematological Oncology · 2025-06 · 43 (S3)
DOI: 10.1002/hon.70096_839 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 15.06.2025. Verfasst von P. Marlton und 13 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Marlton, P., Kesavan, M., Claus, R., Sportoletti, P., Argüello‐Tomás, M., Bosch, F., Ghia, P., Bucher, R., Jin, H. Y., Chen, J., Breton, V., Sugidono, M., Breuleux, M., & Wierda, W. (2025). 839 | AN ONGOING PHASE Ib TRIAL ASSESSING MOSUNETUZUMAB MONOTHERAPY AND COMBINED MOSUNETUZUMAB AND VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. Hematological Oncology, 43(S3). https://doi.org/10.1002/hon.70096_839
Vancouver
Marlton P, Kesavan M, Claus R, Sportoletti P, Argüello‐Tomás M, Bosch F, et al. 839 | AN ONGOING PHASE Ib TRIAL ASSESSING MOSUNETUZUMAB MONOTHERAPY AND COMBINED MOSUNETUZUMAB AND VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. Hematological Oncology. 2025;43(S3). doi:10.1002/hon.70096_839
BibTeX
@article{Marlton2025,
author = {Marlton, P. and Kesavan, M. and Claus, R. and Sportoletti, P. and Argüello‐Tomás, M. and Bosch, F. and Ghia, P. and Bucher, R. and Jin, H. Y. and Chen, J. and Breton, V. and Sugidono, M. and Breuleux, M. and Wierda, W.},
title = {839 | AN ONGOING PHASE Ib TRIAL ASSESSING MOSUNETUZUMAB MONOTHERAPY AND COMBINED MOSUNETUZUMAB AND VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA},
journal = {Hematological Oncology},
year = {2025},
volume = {43},
number = {S3},
doi = {10.1002/hon.70096_839}
}
EUVIMED